Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Dacke Industri AB acquires 71.5 % of the shares in Exertus Oy

Dacke Industri has, by the 23rd of June, completed the acquisition of 71.5 % of the shares in Exertus Oy. The current management and owners will remain as owners with 28.5% of the shares. The intention with the acquisition is to continue together, in partnership, on the exciting journey that Exertus have started and with a clear ambition to internationalize the business further. The acquisition is completely in line with Dacke Industri's ambition to grow with companies that focus on their own products as well as customized components and systems.Exertus is specialized on control systems

KLAR Partners funds take the next step in building the Nordic region's leading technical installation and property services group by acquiring Finnish Quattro Mikenti Group, QMG

Funds advised by KLAR Partners Limited (“KLAR Partners” or “KLAR”) have signed an agreement to acquire QMG, one of Finland's leading players in technical installation and services within electricity, heating, ventilation, sprinklers and automation. The acquisition is the next step in KLAR Partners' ambition to create the Nordic region's leading player in technical installation and property services.QMG offers technical installation and services within electricity, heating, ventilation, sprinklers and automation. With around 1,000 employees in almost 30 locations, the company is one of the

Lynparza approved in China for prostate cancer

24 June 2021 07:00 BST Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival versusnew hormonal treatments in advanced prostate cancer First PARP inhibitor approved in China in advanced prostate cancer AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal

Lifco acquires Next Hydraulics Srl in Italy

Lifco  has signed an agreement to acquire a majority of the shares in Next Hydraulics Srl . The company is a leading manufacturer of telescopic cranes mainly used on light vehicles and produces also stabilizers for vehicles. Next Hydraulics has 43 employees and reported net sales of approximately MEUR 21 in 2020. The company is based in Boretto, Italy. Next Hydraulics will be consolidated in Business Area Systems Solutions, division Service and Distribution. Consolidation is expected to take place in July, 2021.The acquisition will not have

Sweco acquires Boydens Engineering

Sweco has signed an agreement to acquire Belgian consultancy Boydens Engineering, with a strong reputation in the field of designing innovative and sustainable buildings.Boydens Engineering was established in 1961 and is specialised in sustainable building projects in the public and private sectors. Boydens Engineering offers sector-leading expertise in mechanical, electrical, plumbing and fire safety design and is especially known for the design of sustainable ‘net zero-emission’ buildings.  Boydens Engineering employs more than 150 specialists, half of which are working from offices in

Read original

Trading in tbd30’s class a shares on Nasdaq Stockholm commences today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. tbd30 AB (publ) ("tbd30" or the "Company") today announces the outcome of the offering of Class A shares to the general public in Sweden and to institutional investors in Sweden and internationally (the “

YIT to build a parking hall in Kupittaa, Turku

YIT has signed a contract with Turku Technology Properties Ltd on the construction of a parking hall near the Kupittaa railway station, a few kilometres from the centre of Turku. The total value of the project for YIT is nearly EUR 24 million, and it will be recorded in the order book for the second quarter of the year.The nearly 30,000-square-metre parking hall will have space for approximately 1,000 cars and 90 bicycles. Kupittaa is one of the fastest developing areas in Turku, with plenty of business and office space as well as housing and health care services. There are also plans

Peab builds apartments in Oslo

Peab has been commissioned to build 59 apartments in Ammerud in Oslo. The customer is Møllerveien 2 AS, owned by Fredensborg Bolig, and the contract is worth NOK 183 million.The project entails building 59 apartments in two buildings and with commercial space on the ground floor. The basement level will include among other things parking spaces. “We’re proud to continue our good collaboration with Fredensborg Bolig after having recently worked together on the project Waldemars Tårn at Alexander Kielland Square in Oslo,” says Trond Ormstad, Region Manager Peab. The project is a turnkey

Neles to publish its Half-Year Review for January-June 2021 on July 23, 2021

Neles Corporation, press release, June 24, 2021, at 09:00 a.m. EESTNeles will publish its Half-Year Review for January-June 2021 on Friday, July 23, 2021, approximately at 9:00 AM EEST. A teleconference hosted by President and CEO Olli Isotalo and CFO Simo Sääskilahti will be held on the same day at 2:00 PM EEST. To register as a participant for the teleconference and Q&A session, please dial in 5 to 10 minutes before the beginning of the event using the confirmation code and numbers below. The teleconference will be recorded and published on Neles’ website. The contact information is

Scandion Oncology reports positive interim results from the CORIST Phase II study

Scandion Oncology A/S today reports positive results from the dose-finding part 1 of the CORIST Phase II study. A well tolerated dose of SCO-101 in combination with the chemotherapy regimen FOLFIRI has been determined and the SCO-101 treatment in the optimized combination resulted in notable potentiation of the biological activity of FOLFIRI. Furthermore, the CORIST study has identified the oncogene RAS as a predictive biomarker, which will be used to optimize the inclusion of patients in part 2. These positive data, have significantly de-risked the further development of SCO-101 and the

Nel ASA: Signs frame agreement with Howden for supply of hydrogen compressors

(Oslo, 24 June 2021) Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), has signed a framework agreement with leading manufacturer of gas handling solutions, Howden, for supply of hydrogen compressors for Nel’s electrolysers. “We are pleased to enter into this frame agreement with Howden, which ties into the ambitions we announced at our Capital Markets Day and reiterated in our Q1 2021 report around forming strategic partnerships. Working with Howden allows us to optimize our offerings towards existing and future customers” says Jon André Løkke, chief executive officer of

Adelis exits Quattro Mikenti Group (”QMG”)

Adelis Equity Partners Fund I AB (“Adelis”) sells its majority stake in the technical installation group Quattro Mikenti Group to KLAR Partners, which already owns the Sandbäckens Group in Sweden.Adelis invested in the Quattro Mikenti Group in 2017 together with the company's management and key personnel. During Adelis' ownership, the Group's revenues in Finland have doubled from approximately EUR 100 million to approximately EUR 200 million and EBIT has increased approximately fivefold. At the same time, services share of total revenue has grown significantly to more than 50 percent of

SmartCraft ASA goes public after raising NOK 500 million, targeting continued growth

SmartCraft ASA | Non-regulatory press releasesNOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. SmartCraft goes public after raising NOK 500 million, targeting continued growth 24 June 2021 – With a mission of simplifying business for construction companies and craftsmen, the SaaS company SmartCraft goes public on Oslo Børs today,

SmartCraft ASA – Stabilization and over-allotment notice

SmartCraft ASA | Additional regulated information required to be disclosed under the laws of a member stateNOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. SmartCraft ASA – Stabilization and over-allotment notice Oslo, 24 June 2021. Reference is made to the announcement made on 22 June 2021 whereby SmartCraft ASA ("SmartCraft" or

Skanska invests USD 225M, about SEK 1.9 billion, in the office development project 1550 on the Green in Houston, Texas, USA

Skanska invests USD 225M, about SEK 1.9 billion, in the office development project 1550 on the Green in Houston, Texas, USA. The construction contract is worth USD 125M, about SEK 1.1 billion, which will be included in the US order bookings for the second quarter 2021. The international law firm Norton Rose Fulbright has signed a 15-year lease for about 30 percent of the building.Located at 1550 Lamar Street, adjacent to Discovery Green, in downtown Houston, Skanska plans to develop and build a 28-floor, 34,800 square meter office tower. 1550 on the Green will be the first part of a three-

Stabilisation notice

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.DNB Markets, a part of DNB Bank ASA, Sweden Branch ("DNB"), acting in its capacity as stabilisation manager, notifies that stabilisation measures have been undertaken in the Aros Bostadsutveckling AB (publ) ("Aros

Positive data of uTREAT® in glioblastoma provides “green light” to proceed with next steps

The biodistribution results from Curasight A/S’ (“Curasight”) testing of uTREAT® for the treatment of glioblastoma are now available. The results are positive and provide “green light” to proceed to the next step.As previously communicated, Curasight’s therapeutic technology uTREAT®, a uPAR-targeted radionuclide therapy, entered into preclinical testing in glioblastoma. The first step in testing new targeted radionuclides is the study of biodistribution, where both the binding to the implanted human glioblastoma tumors as well as distribution to organs are tested. The binding to the tumor

Investors can now assess the impact of financial portfolios on nature, people and society

“Integrating ESG risk is mainstream – impact is the new sustainability frontier for investors” says new reportGLAND, SWITZERLAND, 24 June 2021 - A pioneering report for the first time identifies tools and services to help portfolio managers and other financial institutions look beyond ESG risk and assess the impacts of financial portfolios on the environment, people and society. The new report by WWF Assessing portfolio impacts: Tools to measure biodiversity and SDG footprints of financial portfolios analyses emerging tools that quantify portfolio ESG impacts and generate information

FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease

Stockholm, 23 June 2021 - BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease.Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. The benefits of a Breakthrough Therapy designation include more intensive guidance on an efficient development

Fiskars upgrades its outlook for 2021

Fiskars CorporationInsider informationJune 23, 2021 at 22:00 EEST Fiskars upgrades its outlook for 2021 Fiskars upgrades its outlook for 2021 as the company’s financial performance in the second quarter has been better than previously expected. The company now expects the comparable EBITA for 2021 to be in the range of EUR 140-160 million. According to the previous outlook issued on April 19, 2021, the comparable EBITA in 2021 was expected to be in the range of EUR 130-145 million. The updated outlook for 2021:In 2021, comparable EBITA is expected to be in the range of EUR

SHAMARAN ANNOUNCES ANNUAL GENERAL MEETING RESULTS

Vancouver, BC, June 23, 2021 /CNW/ - ShaMaran Petroleum Corp. (“ShaMaran” or the “Company”) (SNM: TSXV and Nasdaq First North Growth Market (Sweden)) is pleased to report that at the Company’s Annual General Meeting (the “Meeting”) held today in Vancouver, shareholders received the consolidated audited financial statements of the Company for the year ended December 31, 2020 and approved all of the resolutions put forward at the Meeting, namely: 1. Appointed PricewaterhouseCoopers SA, as auditor of the Company for the ensuing year and authorized the directors to fix their remuneration;

Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While a 25% reduction in menstrual migraine days was achieved across the patient population, a statistically significant difference compared to placebo was not obtained for the study’s primary and secondary endpoints. The study confirms a positive safety and tolerability profile for Sepranolone. Asarina Pharma will continue its fully financed development program for Sepranolone in Tourette syndrome.CEO Peter Nordkild: “Obviously we had

Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021

Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held its annual general meeting (“AGM”) at which the following principal resolutions were passed.Adoption of income statement and balance sheet for the financial year 2020 and discharge from liability The AGM resolved to adopt the income statements for the financial year 2020 as well as the balance sheets as of 31 December 2020, as set out in the annual report for the Company and the group. The members of the Board of Directors and the managing director were discharged

Ethiopian Starts Operating Flights with Fully Vaccinated Crew

Ethiopian Airlines Group, Africa’s largest carrier, has started operating flights with fully vaccinated crew against COVID-19 to keep travelers safe in light of the pandemic.Ethiopian Airlines Group CEO Mr. Tewolde GebreMariam said “We are pleased to operate flights with fully vaccinated crew – a significant step in protecting our employees’ and customers’ health safety. We are encouraged by the increasing number of passengers travelling for business, VFR and tourism supported by the confidence of vaccination across the world. We have been squarely focused on working very hard to ensure the

There are no items matching the current filter
There are no more items matching the current filter
Back to top